Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply ...

As Adam Fein of Drug Channels Institute puts it, these forces are finally puncturing the “ gross-to-net bubble ”—the vast gap ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.

The latest round of Medicare price cuts affect 15 drugs, including Xtandi, an older prostate cancer drug from Pfizer and Astellas Pharma Inc. that will face a 48% discount off its 2024 list price. GSK ...

Novo Nordisk filed for U.S. approval of a higher dose of its Wegovy weight-loss injection, with a decision expected within a month or two. The Danish drugmaker submitted an application for Wegovy 7.2 ...

CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit weight-loss drugs didn't slow the progress of Alzheimer's disease. Novo ...

Amycretin showed statistically significant weight loss of up to 14.5% at 36 weeks Amycretin demonstrated statistically significant reductions in HbA 1c with up to 89.1% achieving HbA 1c levels below 7 ...

Novo Nordisk stock has plunged by 70% from its highest point in 2024. The company’s business is facing major headwinds this year. Competition from the likes of Eli Lilly and Pfizer has soared. Novo ...

Shares of Novo Nordisk A/S took a dive in early Monday trading after the drugmaker said oral semaglutide, which is the key ingredient in the company’s Ozempic and Wegovy diabetes and weight-loss drugs ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, drugmaker Novo Nordisk ...